@article{9b227567ce9f4c6e831fe2ebb52fb4c1,
title = "[Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Pro].",
keywords = "GEFITINIB, 1ST-LINE, CANCER",
author = "Wolfgang Br{\"u}ckl",
note = "Prof. Dr. med. Wolfgang Br{\"u}ckl, Leiter der pneumologischen Onkologie, Medizinische Klinik 3, Lungentumorzentrum N{\"u}rnberg, Prof.-Ernst-Nathan-Str. 1, 90419 N{\"u}rnberg",
year = "2012",
doi = "10.1055/s-0031-1298873",
language = "Deutsch",
volume = "137",
pages = "592",
journal = "DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT",
issn = "0012-0472",
publisher = "Thieme Medical Publishers, US ",
number = "12",
}